# Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

> **NCT01217944** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 277 (actual)

## Conditions studied

- Pathological Myopia

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Verteporfin PDT
- **DRUG:** Sham Ranibizumab
- **DRUG:** Sham verteporfin PDT

## Key facts

- **NCT ID:** NCT01217944
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217944, "Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01217944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*